Dr. Luke Donald Halder Email and Phone Number

I am currently working on extracellular vesicle research in pulmonary infection and inflammation

I have worked to understand molecular mechanism of small cell lung cancer.

I am have worked on defining the microRNA content of extracellular vesicles (EVs) generated from immune cells during Candida albicans infection. My recent research shows that human miRNA, upregulated during the infection, are delivered from host cells to the pathogen by EVs. one of these microRNA induces regulation of the TLR4-NFΚB pathway during C. albicans infection. At the same time, I have actively participated in the research of complement protein Factor H-related protein 1 (FHR1)-mediated inflammation during atherosclerosis, particularly EV bound FHR1 and also understanding of the inflammatory signal generation in dendritic cells by a C. albicans moonlighting protein.

I have described the event of extracellular vesicle (EV) formation, particularly by human monocytes in C. albicans infection. Characterizing the EVs revealed the presence of anti-inflammatory cytokines, which in turn modulate the early infection process in a way that benefits the pathogen (doi: 10.1038/s41467-020-16241-5). In relation to that, I have described the receptor-ligand interaction required for such cytokine carrying EV generation. I was also involved in different research projects related to complement system biology. These include C3 proteins cleavage by Kallikrein and activation of the complement system (doi: 10.1159/000484257), ApoE attenuating unresolved inflammation by complexing with C1q particularly in atherosclerosis and Alzheimer’s disease (doi: 10.1038/s41591-018-0336-8), and FHR1 inducing inflammasome in monocytes particularly in antibody-associated vasculitis (doi: 10.1038/s41467-019-10766-0).

I have described the extracellular trap (ET) formation by neutrophil and monocyte and their effect during Candida albicans infection (doi: 10.3389/fimmu.2016.00671).

Establishment of Live-cell imaging

Major Job Description: ensuring manufacturing (dispensing, formulation, filling, and autoclaving) and packaging operations of insulin, inhaler, prefilled syringe products with GMP standard.